Plasmacytoma Clinical Trial
Official title:
Phase I/II Trial of Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma
This project aims to propose a new approach in the treatment of solitary plasmacytoma: hypofractionated irradiation alone with stereotactic technique that may contribute to the successful treatment of this disease. This work aims to apply this new technique with the primary objective of reducing the progression-free survival for multiple myeloma of patients treated for solitary plasmacytoma, as well as quantify overall survival, local control, toxicities and quality of life in a phase I trial / II.
Solitary plasmacytoma is a rare disease whose treatment has not evolved much in the last decades. The role of radiotherapy in the curative treatment of this entity was defined in a major publication in the 1980s and has since been proven to be the best practice in several other comparative trials, mostly retrospective. The radiotherapy dose of curative intent has also been described over the same period and remains unchanged to this day. Thus, local control, disease cure rate, and rate and progression time for multiple myeloma have been unaffected for almost 30 years. Radiobiology of plasmacytoma cells is also not widely studied. The alpha / beta ratio, which defines the pattern of response of this disease to radiotherapy fractions and its response time, is also not well described. However, it is believed to be smaller in comparison to other hematological malignancies due to reports of cases of intrinsic radioresistance and late recurrence and reports of success with hypofractionated dose in isolated cases where stereotactic techniques were used such as base of skull and spine. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02506959 -
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT02921893 -
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
|
Early Phase 1 | |
| Active, not recruiting |
NCT04174196 -
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
|
Phase 2 | |
| Active, not recruiting |
NCT02544308 -
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
|
Phase 3 | |
| Recruiting |
NCT03031730 -
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02184533 -
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT00421525 -
Phase I/II Study of hLL1 in Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04065308 -
Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
|
Phase 2 | |
| Completed |
NCT02547662 -
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
|
Phase 2 | |
| Terminated |
NCT00109889 -
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
|
Phase 2 |